Discover the link between REM sleep and Alzheimer's disease. Learn how delayed REM sleep may indicate elevated protein levels associated with the disease.

Scientists have uncovered a potential link between delayed REM sleep and Alzheimer's disease. A new study shows that individuals who take longer to enter the dream phase of sleep may be at higher risk of developing the condition.

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.

The approval is the first to come from the FDA since the Trump administration paused external communication by health agencies last week.